• Patricia Bradford, Antimicrobial Development Specialists LLC (US)
  • Alita Miller, Entasis Therapeutics (US)

Moderator: Michael Mourez, École d’Ingénieurs de PURPAN (France)


Screen to pre-clinical candidate (Alita Miller):

  • Discovery strategies
  • Hit-to-lead generation
  • MOA studies
  • Spectrum of activity
  • Resistance studies
  • In vitro toxicity assessments
  • PK/PD characterization

Pre-clinical candidate to phase 1 (Patricia Bradford):

  • Non-clinical package requirements for first-in-human studies
  • Dose selection
  • Non-clinical toxicity
  • CMC considerations
  • Regulatory process/pathways

The presentations were followed by a Q&A session.

This live webinar including interactive Q&A session was broadcast on 25 February 2021.

If you have questions or comments, please let us know: revive@gardp.org.

Download the speakers’ slides here